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nephrotic syndrome. (3) Loci rs5370 and 3A/4A are related to the
plasma cholesterol level in NS children.
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Background: Current evidence indicates that endothelin-1 (ET-1)
plays a physiological role in kidney collecting ducts by inhibiting
Na+ reabsorption. Conversely, experimental models of renal disease
suggest that ET-1 contributes to pathological processes by increasing
vasoconstriction and stimulating ﬁbrosis. ELDP is a recently identiﬁed
EDN1 gene product (preproET-1 [93–166]) that is co-synthesised and
co-released with ET-1. To investigate whether ELDP plays a role in the
pathological changes occurring in chronic kidney disease (CKD), or
may act as a biomarker for disease severity we assayed ELDP levels in
urine and plasma samples from control subjects and patients with CKD.
Methods and results: A speciﬁc double-recognition site sandwich ELISA
for ELDP was optimised for urine and plasma measurements. Patients
recruited to this study had renal disease without co-existing morbid-
ities. Venous plasma and urine samples were collected after a 12 h
fast and stored frozen at −80 °C until analysis. Plasma levels of ELDP
(mean ± SD) were 6.34 ± 1.4 for control subjects and 6.16 ± 1.43,
7.01 ± 2.15, 7.74 ± 1.64, 8.96 ± 3.82 and 12.35 ± 4.45 pmol/L for CKD
stages 1 to 5 respectively (P b 0.05 for the trend). Urine samples
showedmarked variation with no statistically signiﬁcant pattern. Mean
urine levels were 1.08 ± 1.19 pmol/L, with N200 fold difference be-
tween the minimum and maximum values of 0.03 and 6.65 pmol/L.
Conclusions: The trend for increased plasma ELDP in patients with CKD
adds further evidence to the concept that increased expression of EDN1
contributes to the vascular changes in these patients. The factors
affecting urinary levels of ELDP merit further investigation.
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Alterations in the microcirculation in the renal cortex or renal
medulla have been shown as a factor contributing to the develop-
ment of renal dysfunction in sepsis despite normal or increased
global renal blood ﬂow (RBF). Sepsis-induced renal microvascular
alterations (vasoconstriction, capillary leak syndrome with tissue
edema, leukocyte and platelet adhesion with endothelial dysfunction
and/or microthrombosis) could contribute to an increase in renal
vascular resistance in sepsis. Endothelin (ET)-1, a potent vasoconstric-
tor, has been implicated in the pathogenesis of sepsis and in our
previous study we have shown that ET-1 is highly upregulated in renal
tissues as well as in plasma after LPS administration and there is a
potential imbalance in the renal tissue expression of vasoregulatory
molecules. In the current study we investigated whether landiolol
hydrochloride, an ultra-short-acting β-blocker, can play an important
role in ameliorating the LPS-induced upregulated renal HIF-1alpha–ET-
1 system with inﬂammatory cytokine (TNF-alpha) in a rat model of
endotoxemia. Male Wistar rats at 8 weeks of age were administered
lipopolysaccharide (LPS) for 3 h and some LPS-administered rats were
continuously treated with landiolol for 3 h. At 3 h after LPS administra-
tion, both circulatory and renal TNF-alpha levels increased. In addition,
LPS induced a signiﬁcant upregulated expression of ET-1andHIF-1alpha
in the renal tissues compared to control. Finally, treatment of LPS-
administered rats with landiolol for 3 h potentially normalized the
upregulated renal TNF-alpha level as well as the HIF-1alpha–ET-1
system. These data taken together, led us to conclude that landiololmay
be renal protective in endotoxemia modulating the renal microvascular
alteration as well as renal vascular resistance.
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Hypertension-induced nephropathy is accompanied by impaired
renal vascular responsiveness and structural changes, but molecular
mechanisms involved remain elusive. Elevation of intracellular Ca2+
([Ca2+]i) is strongly linked to renal microvascular responses and is
crucial for ET-1-induced contraction of smooth muscle cells (SMC).
The adaptor protein p66 Shc is overexpressed in renal vascular SMC
of hypertensive Dahl S rats. In patch clamp electrophysiology ex-
periments carried out with primary SMCs isolated from renal vessels
of zinc ﬁnger nuclease-mediated p66 Shc rat knockouts, we estab-
lished that p66 Shc deﬁciency results in a dramatic increase in TRPC
channel activity in response to ET-1. Knockout of p66 Shc resulted in
the increase of channel activity. Next we showed that ET-1 produced
dynamic changes in cytosolic Ca2+ concentration in SMCs derived
from p66 Shc knockout rats, when compared with SMCs derived
from their WT littermates. Fura 2-AM was used to measure changes
in the [Ca2+]i before and after administration of 100 nM ET-1. We
also tested activation of [Ca2+]i-dependent signaling pathways in
renal SMCs isolated either from p66 Shc knockouts or from WT
littermates. We have previously shown that ET-1-mediated activa-
tion of calcium regulated cytoplasmic tyrosine kinase Pyk2 caused an
activation of p38 MAP kinase which is known to contribute to actin
remodeling in SMC. Accordingly, we detected increased activation of
Pyk2 and p38 MAP kinase in ET-1-treated SMCs isolated from p66
Shc knockout rats. Our data suggest that p66 Shc restrains activity of
TRPC channels, which mediate inﬂux of Ca2+ in SMC in response to
ET-1, contributing to renal vascular dysfunction.
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